Industry Perspective: Cxbladder Triage AUA Microhematuria Guidelines Inclusion
Jay K. Jhaveri, MD, MPH, discusses the key changes in the 2025 AUA microhematuria guidelines and their implications for clinical practice.
Read MoreJay K. Jhaveri, MD, MPH, is the Senior Medical Director at Pacific Edge Ltd in Hummelstown, Pennsylvania. Dr. Jhaveri specializes in public health, epidemiology, biostatistics, and coding. He has over 15 years of combined clinical, consulting and pharmaceutical industry medical affairs, and clinical development experience.
Dr. Jhaveri received his medical degree from Ross University in Iselin, New Jersey. He completed a residency in General Surgery at the University of California in Irvine. Dr. Jhaveri then completed a research fellowship in prostate cancer outcomes at Weill Cornell, New York Presbyterian Hospital in New York City. He also completed a clinical fellowship in minimally invasive urology surgery at the Henry Ford Health Systems, Vattikuti Urology Institute in Detroit, Michigan. He then received his Master of Public Health with an emphasis in Epidemiology and Biostatics from SUNY Downstate Health Sciences University in New York City.
Dr. Jhaveri has published 118 articles and has been published in several top-tier journals, including the Journal of Clinical Oncology, Journal of Urology, and the Oncologist. Dr. Jhaveri has contributed to medical strategy and training within the pharmaceutical industry with former roles, such as Associate Director of Medical Affairs in the Oncology Department at Bayer Pharmaceuticals, where he oversaw therapeutic development and regulatory compliance. He has also served as Associate Director of US Medical Excellence & Training in the Oncology Department.
Jay K. Jhaveri, MD, MPH, discusses the key changes in the 2025 AUA microhematuria guidelines and their implications for clinical practice.
Read More